TransMedics Group, Inc. (NASDAQ:TMDX) CEO Waleed H. Hassanein Sells 4,000 Shares

TransMedics Group, Inc. (NASDAQ:TMDX) CEO Waleed H. Hassanein sold 4,000 shares of the business’s stock in a transaction dated Wednesday, April 17th. The shares were sold at an average price of $95.12, for a total transaction of $380,480.00. Following the transaction, the chief executive officer now directly owns 74,087 shares in the company, valued at approximately $7,047,155.44. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

TransMedics Group Price Performance

Shares of NASDAQ:TMDX opened at $87.24 on Friday. The company has a current ratio of 9.30, a quick ratio of 8.49 and a debt-to-equity ratio of 3.69. The firm’s 50-day moving average is $82.97 and its two-hundred day moving average is $72.98. TransMedics Group, Inc. has a 1 year low of $36.42 and a 1 year high of $99.63.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Monday, February 26th. The company reported $0.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.22. The company had revenue of $81.20 million for the quarter, compared to analyst estimates of $68.49 million. TransMedics Group had a negative net margin of 10.36% and a negative return on equity of 2.35%. The business’s revenue for the quarter was up 158.6% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.21) earnings per share. Analysts anticipate that TransMedics Group, Inc. will post -0.14 EPS for the current year.

Institutional Trading of TransMedics Group

A number of large investors have recently made changes to their positions in TMDX. Comerica Bank purchased a new stake in shares of TransMedics Group during the third quarter worth approximately $34,000. Global Retirement Partners LLC purchased a new stake in shares of TransMedics Group during the third quarter worth approximately $38,000. Cutler Group LLC CA increased its stake in shares of TransMedics Group by 600.0% during the third quarter. Cutler Group LLC CA now owns 700 shares of the company’s stock worth $38,000 after buying an additional 600 shares during the period. Ancora Advisors LLC purchased a new stake in shares of TransMedics Group during the first quarter worth approximately $38,000. Finally, First Horizon Advisors Inc. increased its stake in shares of TransMedics Group by 45.1% during the first quarter. First Horizon Advisors Inc. now owns 544 shares of the company’s stock worth $41,000 after buying an additional 169 shares during the period. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. JPMorgan Chase & Co. boosted their price target on shares of TransMedics Group from $87.00 to $105.00 and gave the company an “overweight” rating in a research report on Tuesday, February 27th. Piper Sandler started coverage on shares of TransMedics Group in a research report on Thursday, March 28th. They set an “overweight” rating and a $95.00 price target on the stock. Morgan Stanley boosted their price objective on shares of TransMedics Group from $75.00 to $95.00 and gave the company an “equal weight” rating in a report on Wednesday, February 28th. Finally, Oppenheimer boosted their price objective on shares of TransMedics Group from $92.00 to $105.00 and gave the company an “outperform” rating in a report on Tuesday, February 27th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $102.00.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.